文献速递烧伤创面修复

标准治疗与氧雄龙及睾酮在烧伤高代谢中的多中心分析

Multicenter Analysis of Standard of Care versus Oxandrolone versus Testosterone in burn hypermetaboliSm (MASCOTS).
PubMed 文献 · J Burn Care Res · 2026-07-28

这项多中心研究分析了813例2022年6月至2025年6月间美国12家烧伤中心收治的重度烧伤患者,比较睾酮、氧雄龙、人生长激素与无雄激素补充的疗效与安全性。研究发现雄激素补充未改善住院体重维持,但延长住院和ICU时间、增加静脉血栓栓塞事件,且氧雄龙组死亡率高于睾酮组。

要点

  • 雄激素补充未改善烧伤患者住院体重维持(p=0.064)。
  • 雄激素治疗与更长的住院及ICU停留相关(p=0.026)。
  • 氧雄龙组死亡率高于睾酮组(p=0.001),整体死亡率无差异。

核心结论

  • 雄激素补充未改善重度烧伤患者住院体重维持,且与更长住院时间和更高静脉血栓栓塞事件相关。
  • 氧雄龙治疗患者死亡率高于睾酮治疗患者,但整体死亡率在治疗与未治疗组间无差异。

研究设计与样本

  • 多中心研究,纳入2022年6月至2025年6月美国12家烧伤中心813例重度烧伤患者。
  • 按是否接受睾酮、氧雄龙、人生长激素或无雄激素补充分组,采用ANOVA和卡方检验分析,并用倾向性评分匹配调整基线差异。

主要发现

  • 雄激素补充与无补充相比,住院体重维持无改善(p=0.064),中位体重变化无差异。
  • 接受雄激素治疗者住院和ICU停留时间更长(p=0.026)。
  • 整体死亡率在治疗与未治疗组间无差异(p=0.885),但氧雄龙组死亡率高于睾酮组(p=0.001)。
  • 雄激素治疗与更高的静脉血栓栓塞事件发生率相关(p=0.019)。

临床怎么用

  • 烧伤高代谢管理中使用雄激素补充需权衡疗效、安全性与经济考量,关注长期功能结局而非仅住院期间指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Severe burn injury results in a profound hypermetabolic state that complicates management and recovery. Oxandrolone has historically been used to help attenuate this response, but its withdrawal from the United States (US) market has led to increased use of alternative anabolic agents such as testosterone and human growth hormone. However, studies comparing the efficacy and safety between these alternative anabolic agents in adult burn patients remain limited. In this multicenter study, patients were stratified based on if they received testosterone, oxandrolone, human growth hormone, or no anabolic supplementation. Baseline characteristics and clinical outcomes were analyzed with ANOVA and Chi-square testing as appropriate. Propensity score matching was used to adjust for baseline differences in injury severity and patient characteristics. 813 patients who sustained major burn injuries between June 2022 and June 2025 across 12 verified US burn centers were analyzed. Anabolic supplementation was not associated with improved inpatient weight maintenance when compared with no anabolic supplementation (p=0.064), nor with differences in median weight change. Patients receiving anabolic therapy experienced longer hospital and intensive care unit stays (p=0.026). Overall mortality did not differ between treated and untreated patients (p = 0.885); however, mortality was higher among patients treated with oxandrolone compared with testosterone (p=0.001). Anabolic therapy was associated with higher rates of venous thromboembolic events (p = 0.019). These findings underscore that optimizing anabolic therapy will require balancing efficacy, safety, and economic considerations, with a focus on long-term functional outcomes beyond initial hospital stay.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Hong A, Hannan PM, Ivanko A, et al. Multicenter Analysis of Standard of Care versus Oxandrolone versus Testosterone in burn hypermetaboliSm (MASCOTS). J Burn Care Res. 2026. PMID: 42518198. doi:10.1093/jbcr/irag127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。